Aehr Test Systems provides essential wafer-level testing for high-growth sectors like silicon carbide and silicon photonics. C3.ai is transitioning its enterprise software platform toward a consumption-based pricing model to drive broader adoption.
Aehr Test Systems (AEHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The average of price targets set by Wall Street analysts indicates a potential upside of 49.6% in Aehr Test Systems (AEHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aehr's record bookings, AI-driven backlog and expanding burn-in portfolio give it the edge over FormFactor for long-term growth.
After losing some value lately, a hammer chart pattern has been formed for Aehr Test Systems (AEHR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aehr Test Systems transformed from an EV silicon carbide supplier into an AI infrastructure company, with AI processors and silicon photonics generating 91% of revenue. Fourth-quarter bookings surged to a record $60.7 million, lifting effective backlog to approximately $100.6 million and supporting 160%-200% FY2027 revenue growth. Wafer-level burn-in is becoming increasingly critical as larger AI processors integrate HBM memory and chiplets, reducing costly packaging failures.
STT, AEHR and NBIS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 20, 2026.
Here is how Aehr Test Systems (AEHR) and Cisco Systems (CSCO) have performed compared to their sector so far this year.
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.
Aehr Test Systems, Inc. has shifted its narrative from an EV supplier to a diversified AI-driven growth story. FY27 guidance projects 160–200% revenue growth, driven by AI accelerators, CPUs, and network processors, but customer concentration remains a risk. AEHR stock's valuation is high at ~18x FY27 revenue and ~45x gross profit, yet comparable to other AI winners if growth persists.
As AI stocks swing up and down, one name that has felt those movements as much as any is Aehr Test Systems NASDAQ: AEHR. This small stock has risen about 320% in 2026, and sits at a market capitalization of $2.7 billion in mid-July.
I am initiating Aehr Test Systems, Inc. with a Buy rating and a $144 price target, implying 50% upside from $96. The biggest driver is AI burn-in, where the $41 million hyperscale customer order supports my view that AEHR's Sonoma platform is moving from validation into real production demand. I have estimated about $1.0 in incremental EPS contribution, and using a 144x forward non-GAAP P/E multiple gives me a $144 price target, representing about 50% upside.